NEWS

WIRES

OTHER

TechniScan Expands Operational Team to Accelerate Development and Commercialization of Breast Imaging Technology

"We were able to attract experienced and industry-respected senior personnel partly because the controversy surrounding mammography has heightened interest in ultrasound breast imaging technology, especially for use with women under 50," stated Chief Executive Officer David C. Robinson. "One of the unique aspects about these people is that they are all senior-level executives who are still willing to roll up their sleeves and get the work done."

TechniScan has hired Dr. John C. Klock, MD, as the Company's Chief Medical Director; Andy Cier as Director of Marketing and Communications; Jessica Smith, MS, as Senior Regulatory and Market Development Manager; and Louis D. Langholtz as Senior Software Engineer.

Dr. Klock, Chief Medical Director, is a board-certified Internist and Hematologist-Oncologist who has been involved in the start-up of five medical companies. With more than 70 peer-reviewed medical and scientific publications and eight granted U.S. patents to his name, Dr. Klock will be developing TechniScan's training and analytical protocols. He will also be working with Director of Clinical Affairs Karleen Callahan, with Jessica Smith in Regulatory Affairs and with clinical study sites to ensure that the Company's clinical objectives are being met.

Mr. Cier, as Director of Marketing and Communications, is also a marketing consultant and former Partner, General Manager of the Salt Lake office of Riester, an advertising, marketing and PR firm. Mr. Cier will be overseeing the marketing and branding of SVARA^TM, the system that captures, computes and shares ultrasound images of the breast. He will also oversee TechniScan's Investor Relations, Public Relations and Advertising functions for the commercial launch of SVARA^TM, estimated to take place in 2010.

Ms. Smith, Senior Regulatory and Market Development Manager, has a master's in bioengineering and has worked in the medical industry in a variety of roles over the past 15 years, from regulatory affairs to medical writing and market research. Ms. Smith will oversee TechniScan's 510k and other regulatory filings with the FDA, and she will be managing TechniScan's regulatory consultant, the Anson Group.

As Senior Software Engineer, Mr. Langholtz has more than 20 years' systems and applications level programming experience in 20-plus computer languages. His proven background in software programming, particularly with highly advanced embedded systems, will be of significant value in support of the system operation, image processing and application level programming for TechniScan's products.

About TechniScan, Inc.

Based in Salt Lake City, Utah, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system, known as SVARA , uses a process called Warm Bath Ultrasound (WBU ) to provide physicians with automated, 3D, ultrasound images of the physical structures within the breast. TechniScan's WBU imaging device (SVARA ) is limited by US law to investigational use unless and until cleared by the FDA.

For more information, please visit www.techniscanmedical.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company" ) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Press and Media
TechniScan, Inc.
Andy Cier, Dir. of Marketing and Communications
801-521-0444 ext. 129
acier@techniscanmedical.com
or
Investor Relations
Hayden IR
Cameron Donahue, Partner
651-653-1854
cameron@haydenir.com